China Resources Pharmaceutical Group Résultats passés
Passé contrôle des critères 5/6
China Resources Pharmaceutical Group a connu une croissance annuelle moyenne de ses bénéfices de 4.3%, tandis que le secteur Pharmaceuticals a vu ses bénéfices augmenter de en hausse à 5.7% par an. Les revenus ont augmenté de en hausse à un taux moyen de 8% par an. Le rendement des capitaux propres de China Resources Pharmaceutical Group est 8.5% et ses marges nettes sont de 1.5%.
Informations clés
4.3%
Taux de croissance des bénéfices
4.4%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 5.6% |
| Taux de croissance des recettes | 8.0% |
| Rendement des fonds propres | 8.5% |
| Marge nette | 1.5% |
| Dernière mise à jour des bénéfices | 30 Jun 2024 |
Mises à jour récentes des performances passées
Recent updates
China Resources Pharmaceutical Group Limited's (HKG:3320) Shares Climb 34% But Its Business Is Yet to Catch Up
Oct 07
Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly
Aug 30China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Jun 01Subdued Growth No Barrier To China Resources Pharmaceutical Group Limited (HKG:3320) With Shares Advancing 32%
May 13China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697
Apr 28China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Apr 14China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697
Mar 28China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon
Jan 28We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt
Dec 06Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?
Sep 07Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?
Aug 02With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case
May 26These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
May 05China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year
Apr 04Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?
Jan 24Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?
Dec 15China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price
Oct 18China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt
Aug 27China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15
May 29China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15
May 02China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's
Apr 07China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet
Mar 31Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?
Feb 21Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly
Dec 07China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate
Nov 10These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
Aug 29Is China Resources Pharmaceutical Group Limited (HKG:3320) Trading At A 21% Discount?
Aug 03Is China Resources Pharmaceutical Group Limited (HKG:3320) A Good Fit For Your Dividend Portfolio?
May 03Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?
Apr 12Is China Resources Pharmaceutical Group Limited's (HKG:3320) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Mar 17Ventilation des recettes et des dépenses
Comment China Resources Pharmaceutical Group gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Jun 24 | 250,483 | 3,777 | 25,588 | 0 |
| 31 Mar 24 | 247,593 | 3,816 | 25,420 | 0 |
| 31 Dec 23 | 244,704 | 3,854 | 25,252 | 0 |
| 30 Sep 23 | 232,564 | 3,573 | 23,906 | 0 |
| 30 Jun 23 | 224,656 | 3,382 | 22,961 | 0 |
| 31 Mar 23 | 224,587 | 3,518 | 22,783 | 0 |
| 31 Dec 22 | 218,183 | 3,500 | 21,999 | 0 |
| 30 Sep 22 | 221,487 | 3,724 | 22,247 | 0 |
| 30 Jun 22 | 211,788 | 3,719 | 21,193 | 0 |
| 31 Mar 22 | 196,226 | 3,288 | 19,674 | 0 |
| 31 Dec 21 | 193,021 | 3,072 | 19,393 | 0 |
| 30 Sep 21 | 191,495 | 2,869 | 19,667 | 0 |
| 30 Jun 21 | 187,554 | 2,626 | 19,701 | 0 |
| 31 Mar 21 | 179,512 | 2,720 | 19,092 | 0 |
| 31 Dec 20 | 168,762 | 2,776 | 18,197 | 0 |
| 30 Sep 20 | 171,873 | 2,683 | 19,137 | 0 |
| 30 Jun 20 | 174,956 | 2,578 | 20,122 | 0 |
| 31 Mar 20 | 181,054 | 2,793 | 21,233 | 0 |
| 31 Dec 19 | 182,690 | 2,937 | 21,813 | 0 |
| 30 Sep 19 | 183,417 | 3,670 | 21,984 | 0 |
| 30 Jun 19 | 173,938 | 4,187 | 20,930 | 0 |
| 31 Mar 19 | 165,679 | 3,737 | 20,069 | 0 |
| 31 Dec 18 | 166,626 | 3,494 | 20,322 | 0 |
| 30 Sep 18 | 163,734 | 3,466 | 19,540 | 0 |
| 30 Jun 18 | 154,852 | 3,309 | 18,062 | 0 |
| 31 Mar 18 | 142,296 | 2,959 | 15,795 | 0 |
| 31 Dec 17 | 143,688 | 2,901 | 15,087 | 0 |
| 30 Sep 17 | 143,252 | 2,759 | 14,277 | 0 |
| 30 Jun 17 | 142,276 | 2,602 | 13,380 | 0 |
| 31 Mar 17 | 142,003 | 2,577 | 13,395 | 0 |
| 31 Dec 16 | 140,316 | 2,526 | 13,279 | 0 |
| 30 Sep 16 | 132,253 | 2,161 | 12,534 | 0 |
| 30 Jun 16 | 129,313 | 1,889 | 12,274 | 0 |
| 31 Mar 16 | 123,770 | 2,103 | 11,766 | 0 |
| 31 Dec 15 | 122,785 | 2,388 | 11,692 | 0 |
| 31 Dec 14 | 108,575 | 2,116 | 9,955 | 0 |
| 31 Dec 13 | 91,313 | 2,061 | 9,248 | 0 |
Des revenus de qualité: 3320 a des bénéfices de haute qualité.
Augmentation de la marge bénéficiaire: Les marges bénéficiaires nettes actuelles de 3320 sont plus élevées que l'année dernière 3320. (1.5%) sont plus élevées que l'année dernière (1.5%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: Les bénéfices de 3320 ont augmenté de 4.3% par an au cours des 5 dernières années.
Accélération de la croissance: La croissance des bénéfices de 3320 au cours de l'année écoulée ( 11.7% ) dépasse sa moyenne sur 5 ans ( 4.3% par an).
Bénéfices par rapport au secteur d'activité: La croissance des bénéfices 3320 au cours de l'année écoulée ( 11.7% ) a dépassé celle du secteur Pharmaceuticals 9.4%.
Rendement des fonds propres
ROE élevé: Le retour sur capitaux propres de 3320 ( 8.5% ) est considéré comme faible.